As of June 18, 2025, BioMark Diagnostics Inc (BUX.CN) reports a Gross Margin of 100.00%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Comparing BioMark Diagnostics Inc's Gross Margin to Peers
To better understand BioMark Diagnostics Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| BioMark Diagnostics Inc (BUX.CN) | 100.00% |
| Algernon Pharmaceuticals Inc (AGN.CN) | 7775.20% |
| Third Bench Inc (NECA) | 7775.20% |
| Nu-Med Plus Inc (NUMD) | 7775.20% |
| Pharmather Holdings Ltd (PHRM.CN) | 7775.20% |
| Izotropic Corp (IZO.CN) | 7775.20% |
Compared to its competitors, BioMark Diagnostics Inc's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.